Skip to main content

Resultados relacionados

Resultados totales (Incluyendo duplicados): 16
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology

  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Scheeren Brum, Wagner|||0000-0002-9777-0559
  • Molfetta, Guglielmo Di
  • Benedet, Andréa Lessa
  • Arslan, Burak
  • Jonaitis, Erin Mc Mullen
  • Langhough, Rebecca E.
  • Cody, Karly Alex
  • Wilson, Rachael E.
  • Carlsson, Cynthia M.
  • Vanmechelen, Eugeen|||0000-0002-9466-5366
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Rahmouni, Nesrine
  • Tissot, Cécile
  • Stevenson, Jenna
  • Servaes, Stijn|||0000-0002-4431-957X
  • Therriault, Joseph
  • Pascoal, Tharick|||0000-0001-9057-8014
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Johnson, Sterling C.
  • Jeromin, Andreas
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
IMPORTANCE Phosphorylated tau (p-tau) is a specific blood biomarker for Alzheimer disease (AD) pathology, with p-tau217 considered to have the most utility. However, availability of p-tau217 tests for research and clinical use has been limited. Expanding access to this highly accurate AD biomarker is crucial for wider evaluation and implementation of AD blood tests. OBJECTIVE To determine the utility of a novel and commercially available immunoassay for plasma p-tau217 to detect AD pathology and evaluate reference ranges for abnormal amyloid β (Aβ) and longitudinal change across 3 selected cohorts. DESIGN, SETTING, AND PARTICIPANTS This cohort study examined data from 3 single-center observational cohorts: cross-sectional and longitudinal data from the Translational Biomarkers in Aging and Dementia (TRIAD) cohort (visits October 2017-August 2021) and Wisconsin Registry for Alzheimer's Prevention (WRAP) cohort (visits February 2007-November 2020) and cross-sectional data from the Sant Pau Initiative on Neurodegeneration (SPIN) cohort (baseline visits March 2009-November 2021). Participants included individuals with and without cognitive impairment grouped by amyloid and tau (AT) status using PET or CSF biomarkers. Data were analyzed from February to June 2023. EXPOSURES Magnetic resonance imaging, Aβ positron emission tomography (PET), tau PET, cerebrospinal fluid (CSF) biomarkers (Aβ42/40 and p-tau immunoassays), and plasma p-tau217 (ALZpath pTau217 assay). MAIN OUTCOMES AND MEASURES Accuracy of plasma p-tau217 in detecting abnormal amyloid and tau pathology, longitudinal p-tau217 change according to baseline pathology status. RESULTS The study included 786 participants (mean [SD] age, 66.3 [9.7] years; 504 females [64.1%] and 282 males [35.9%]). High accuracy was observed in identifying elevated Aβ (area under the curve [AUC], 0.92-0.96; 95% CI, 0.89-0.99) and tau pathology (AUC, 0.93-0.97; 95% CI, 0.84-0.99) across all cohorts. These accuracies were comparable with CSF biomarkers in determining abnormal PET signal. The detection of abnormal Aβ pathology using a 3-range reference yielded reproducible results and reduced confirmatory testing by approximately 80%. Longitudinally, plasma p-tau217 values showed an annual increase only in Aβ-positive individuals, with the highest increase observed in those with tau positivity. CONCLUSIONS AND RELEVANCE This study found that a commercially available plasma p-tau217 immunoassay accurately identified biological AD, comparable with results using CSF biomarkers, with reproducible cut-offs across cohorts. It detected longitudinal changes, including at the preclinical stage.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Diagnostic performance of plasma pTau 217, pTau 181, Aβ 1-42 and Aβ 1-40 in the LUMIPULSE automated platform for the detection of Alzheimer disease

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Recently developed blood markers for Alzheimer's disease (AD) detection have high accuracy but usually require ultra-sensitive analytic tools not commonly available in clinical laboratories, and their performance in clinical practice is unknown. We analyzed plasma samples from 290 consecutive participants that underwent lumbar puncture in routine clinical practice in a specialized memory clinic (66 cognitively unimpaired, 130 participants with mild cognitive impairment, and 94 with dementia). Participants were classified as amyloid positive (A+) or negative (A-) according to CSF Aβ/Aβ ratio. Plasma pTau, pTau, Aβ and Aβ were measured in the fully-automated LUMIPULSE platform. We used linear regression to compare plasma biomarkers concentrations between A + and A- groups, evaluated Spearman's correlation between plasma and CSF and performed ROC analyses to assess their diagnostic accuracy to detect brain amyloidosis as determined by CSF Aβ/Aβ ratio. We analyzed the potential of pTau to predict amyloidosis in CSF. Plasma pTau and pTau concentration were higher in A + than A- while the plasma Aβ/Aβ ratio was lower in A + compared to A-. pTau and the Aβ/Aβ ratio showed moderate correlation between plasma and CSF (Rho = 0.66 and 0.69, respectively). The areas under the ROC curve to discriminate A + from A- participants were 0.94 (95% CI 0.92-0.97) for pTau, and 0.88 (95% CI 0.84-0.92) for both pTau and Aβ/Aβ. Chronic kidney disease (CKD) was related to increased plasma biomarker concentrations, but ratios were less affected. Plasma pTau had the highest fold change (x4.2) and showed high predictive capability in discriminating A + from A-, having 4-7% misclassification rate. The global accuracy of plasma pTau using a two-threshold approach was robust in symptomatic groups, exceeding 90%. The evaluation of blood biomarkers on an automated platform exhibited high diagnostic accuracy for AD pathophysiology, and pTau showed excellent diagnostic accuracy to identify participants with AD in a consecutive sample representing the routine clinical practice in a specialized memory unit.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

A Novel Splicing Variant in Atypical Presentation of Familial Frontotemporal Lobar Degeneration

  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Bernal, Sara|||0000-0003-4427-0574
  • Almenta Gallego, David|||0000-0001-9069-8948
  • Perez Blanco, Josefina|||0000-0002-6489-8871
  • Camacho, Valle|||0000-0003-0748-0847
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Carbayo Viejo, Álvaro|||0000-0001-9282-8603
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
C-truncating variants in the charged multivesicular body protein 2B (CHMP2B) gene are a rare cause of frontotemporal lobar degeneration (FTLD), previously identified only in Denmark, Belgium, and China. We report a novel CHMP2B splice-site variant (c.35-1G>A) associated with familial FTLD in Spain. The cases were two monozygotic male twins who presented at ages 62 and 66 years with a slowly progressive behavioral variant of frontotemporal dementia and a syndrome mimicking dementia with Lewy bodies, respectively. Functional and in silico analyses supported the pathogenicity of this variant. Our findings contribute new insights into the genetic landscape and clinical heterogeneity of FTLD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Relationship of cognitive decline with glucocerebrosidase activity and amyloid-beta 42 in and

  • Gonzalez, Maria Camila|||0000-0003-1061-4164
  • Oftedal, Linn
  • Lange, Johannes
  • Tovar-Rios, Diego Alejandro
  • Tysnes, Ole-Bjørn
  • Paquet, Claire|||0000-0002-2273-7316
  • Marquié, Marta|||0000-0002-0660-0950
  • Boada, Mercè|||0000-0003-2617-3009
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Rejdak, Konrad
  • Papuc, Ewa
  • Hort, Jakub|||0000-0002-1080-3726
  • Falup-Pecurariu, Cristian
  • Aarsland, Dag|||0000-0001-6314-216X
  • Alves, Guido
  • Maple-Grødem, Jodi
Dementia with Lewy bodies (DLB) and Parkinson's disease (PD) share clinical, pathological, and genetic risk factors, including GBA1 and APOEε4 mutations. Biomarkers associated with the pathways of these mutations, such as glucocerebrosidase enzyme (GCase) activity and amyloid-beta 42 (Aβ42) levels, may hold potential as predictive indicators, providing valuable insights into the likelihood of cognitive decline within these diagnoses. Our objective was to determine their association with cognitive decline in DLB and PD. A total of 121 DLB patients from the European-DLB Consortium and 117 PD patients from the Norwegian ParkWest Study were included in this study. The four most commonly associated variants of GBA1 mutations (E326K, T369M, N370S, L444P), APOEε4 status, and cerebrospinal fluid (CSF) Aβ42 levels and GCase activity were assessed, as well as global cognition using the Mini-Mental State Examination. Linear mixed-effects regression models were used to evaluate the association of CSF biomarkers with cognitive decline in each diagnostic group, adjusted for age, sex, education, and genetic mutation profile. Low CSF Aβ42 levels were associated with accelerated cognitive decline in DLB, whereas reduced CSF GCase activity predicted faster cognitive decline in PD. These associations were independent of GBA1 gene mutations or APOEε4 status. Our study provides important evidence on the relationship between brain Aβ deposition and GCase activity in the Lewy body disease spectrum independent of their genetic mutation profile. This information could be relevant for designing future clinical trials targeting these pathways.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome

  • Sauer, M.
  • Gomes, B.F.
  • Shahrouki, P.
  • Lantero Rodríguez, Juan|||0000-0002-7426-678X
  • Montoliu Gaya, Laia|||0000-0001-7684-6318
  • Camporesi, E.
  • Belbin, Olivia|||0000-0002-6109-6371
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Kumar, A.
  • Sharma, M.
  • Singh, S.
  • Brinkmalm, G.
  • Gobom, J.
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Schöll, M.
  • Janelidze, S.
  • Deep, G.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Brinkmalm, A.
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Hansson, Oskar|||0000-0001-8467-7286
  • Ashton, Nicholas J.|||0000-0002-3579-8804
  • Nilsson, J.
INTRODUCTION: Synaptic dysfunction and loss are pathological hallmarks of neurodegenerative diseases. Neuronal pentraxin 2 (NPTX2), a presynaptic protein involved in synaptic plasticity, has been linked to cognitive decline in Alzheimer's disease (AD) and other neurodegenerative disorders. METHODS: We developed and validated a novel single molecule array (Simoa) for NPTX2 in cerebrospinal fluid, which was evaluated in two independent cohorts. RESULTS: CSF NPTX2 concentration was lower (fold change [FC] 0.82, p < 0.01) in AD patients and Down syndrome individuals (FC 0.56, p < 0.001), compared with cognitively unimpaired patients (CU). It was also associated with Mini-Mental State Examination (MMSE) score (β = 2.51, p < 0.001), tau-PET (β = -0.21, p < 0.01), and cortical thickness (β = 0.08, p < 0.001). DISCUSSION: We describe the first assay for NPTX2 on the Simoa platform, where we continue to highlight the valuable addition of NPTX2 to routine diagnostics of suspected cognitive impairment in patients as it associates better with cognition than other, more established AD biomarkers. Highlights: Novel method validated for measuring CSF NPTX2 on semi-automated Simoa platform. Method validated for use in CSF, where it shows a significant decrease in both AD and DS patients. Associated with cognition, neurofibrillary tangles, and cortical thickness in AD patients. Associations with cognition are shown to be stronger than those of pTau and NFL.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Prospective evaluation of plasma pTau217 stability for the detection of Alzheimer's disease in a tertiary memory clinic

  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Ferrer Pérez, Rosa|||0009-0004-9477-699X
  • Zhu, Nuole|||0000-0002-0015-9455
  • Rubio Guerra, Sara|||0000-0001-7652-8029
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Arriola-Infante, J.E.
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Garcia Castro, Jesús|||0000-0003-1503-4775
  • Selma Gonzalez, Judit|||0009-0006-1021-4653
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Knowledge on the effect of analytical variability and storage conditions are essential for the successful implementation of plasma pTau in prospective settings. Aims: To investigate the performance of plasma pTau, measured in consecutive samples with LUMIPULSE, for detecting Alzheimer's disease in a prospective memory clinic setting, along with evaluating its pre-analytical and analytical stability. Methods: We prospectively measured pTau using the LUMIPULSE automated platform in consecutive patient plasma samples collected between May and November 2024 at the Sant Pau Memory Unit (Barcelona). A subset of participants also underwent paired lumbar puncture for CSF AD biomarkers. We compared biomarker concentrations under different short-term storage conditions (4ºC vs -20ºC) and different protocol pipelines, and assessed lot-to-lot variability. In the subset with available CSF biomarkers, logistic regression was used to evaluate the association between plasma pTau217 and the likelihood of a positive (A +) or a negative (A-) CSF amyloid status. Using ROC analysis, in this prospective cohort we evaluated the accuracy of previously established thresholds derived from historical samples. Results: We included 280 participants, divided into two groups: those with (n = 109) and without CSF data (n = 171). Among the subset with CSF, 48% were A +, with a plasma pTau fold-change of 4.5 × compared to A-. We found no differences in plasma pTau concentrations between either short-term storage conditions. The overall coefficients of analytical variation ranged from 1.8% to 3.2%. Plasma pTau concentrations were slightly higher in paired samples of the clinical protocol. Following a two-threshold approach, the need of confirmatory tests (grey zones) after measuring plasma pTau ranged between 45.9% and 18.3% using our previously reported strict or lenient cutoffs (overall accuracy 96.6% and 92.1%, respectively). Conclusions: The robust stability and low lot-to-lot variability of plasma pTau measurement in an automated platform result in high diagnostic performance of this biomarker in the prospective evaluation of patients in a memory clinic setting. These findings support its implementation into clinical routine, offering clinicians an accessible biomarker for AD diagnosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Associations of Microbleeds and Their Topography With Imaging and CSF Biomarkers of Alzheimer Pathology in Individuals With Down Syndrome

  • Zsadanyi, Sara E.|||0000-0002-2033-5989
  • Morcillo Nieto, Alejandra O.|||0000-0003-2202-3521
  • Aranha, Mateus|||0000-0001-9594-292X
  • Aragón, Irina
  • Arriola Infante, José Enrique|||0000-0002-3298-4601
  • Vaqué-Alcázar, Lídia|||0000-0002-6776-6559
  • Montal, Victor|||0000-0002-5714-9282
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Rodríguez-Baz, Íñigo|||0000-0003-3039-9115
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Hoyo Soriano, Laura del|||0000-0003-4372-1599
  • Benejam, Bessy|||0000-0002-6789-8615
  • Fernández, S.
  • Bargalló, Núria|||0000-0001-6284-5402
  • González-Ortiz, Sofía|||0000-0003-2578-6671
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Belbin, Olivia|||0000-0002-6109-6371
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Giménez, Sandra|||0000-0001-8031-2319
  • Maure Blesa, Lucia|||0000-0001-5643-7971
  • Hernandez, Aida S.
Background and Objectives Cerebral hemorrhages are an exclusion criterion and potential adverse effect of antiamyloid agents. It is, therefore, critical to characterize the natural history of cerebral microbleeds in populations genetically predisposed to Alzheimer disease (AD), such as Down syndrome (DS). We aimed to assess microbleed emergence in adults with DS across the AD spectrum, defining their topography and associations with clinical variables, cognitive outcomes, and fluid and neuroimaging biomarkers. Methods This cross-sectional study included participants aged 18 years or older from the Down-Alzheimer Barcelona Neuroimaging Initiative and Sant Pau Initiative on Neurodegeneration with T1-weighted and susceptibility-weighted images. Participants underwent comprehensive assessments, including apolipoprotein E (APOE) genotyping; fluid and plasma determinations of beta-amyloid, tau, and neurofilament light; cognitive outcomes (Cambridge Cognitive Examination and modified Cued Recall Test); and vascular risk factors (hypertension, diabetes mellitus, and dyslipidemia). We manually segmented microbleeds and characterized their topography. Associations between microbleed severity and AD biomarkers were explored using between-group comparisons (none vs 1 vs 2+) and multivariate linear models. Results We included 276 individuals with DS and 158 healthy euploid controls (mean age = 47.8 years, 50.92% female). Individuals with DS were more likely to have microbleeds than controls (20% vs 8.9%, p < 0.001), with more severe presentation (12% with 2+ vs 1.9%). Microbleeds increased with age (12% 20-30 years vs 60% > 60 years) and AD clinical stage (12.42% asymptomatic, 27.9% prodromal, 35.09% dementia) were more common in APOEe4 carriers (26% vs 18.3% noncarriers, p = 0.008), but not associated with vascular risk factors (p > 0.05). Microbleeds were predominantly posterior (cerebellum 33.66%; occipital 14.85%; temporal 21.29%) in participants with DS. Associations with microbleed severity were found for neuroimaging and fluid AD biomarkers, but only hippocampal volumes (standardized β = -0.18 [-0.31, -0.06], p < 0.005) and CSF p-tau-181 concentrations (β = 0.26 [0.12, 0.41], p < 0.005) survived regression controlling for age and disease stage, respectively. Microbleeds had limited effect on cognitive outcomes. Discussion In participants with DS, microbleeds present with a posterior, lobar predominance, are associated with disease severity, but do not affect cognitive performance. These results suggest an interplay between AD pathology and vascular lesions, implicating microbleeds as a risk factor limiting the use of antiamyloid agents in this population.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Subirana, Andrea
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Vanderstichele, Hugo
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Objective: We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)-derived peptides related to the amyloidogenic pathway, cortical thickness, neuropsychological performance, and cortical gene expression profiles in frontotemporal lobar degeneration (FTLD)-related syndromes, Alzheimer's disease (AD), and healthy controls. Methods: We included 214 participants with CSF available recruited at two centers: 93 with FTLD-related syndromes, 57 patients with AD, and 64 healthy controls. CSF levels of amyloid β (Aβ)1-42, Aβ1-40, Aβ1-38, and soluble β fragment of APP (sAPPβ) were centrally analyzed. We compared CSF levels of APP-derived peptides between groups and, we studied the correlation between CSF biomarkers, cortical thickness, and domain-specific cognitive composites in each group. Then, we explored the relationship between cortical thickness, CSF levels of APP-derived peptides, and regional gene expression profile using a brain-wide regional gene expression data in combination with gene set enrichment analysis. Results: The CSF levels of Aβ1-40, Aβ1-38, and sAPPβ were lower in the FTLD-related syndromes group than in the AD and healthy controls group. CSF levels of all APP-derived peptides showed a positive correlation with cortical thickness and the executive cognitive composite in the FTLD-related syndromes group but not in the healthy control or AD groups. In the cortical regions where we observed a significant association between cortical thickness and CSF levels of APP-derived peptides, we found a reduced expression of genes related to synaptic function. Interpretation: APP-derived peptides in CSF may reflect FTLD-related neurodegeneration. This observation has important implications as Aβ1-42 levels are considered an indirect biomarker of cerebral amyloidosis.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse

  • Alcolea, Daniel|||0000-0002-3819-3245
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Muñoz, Laia|||0000-0003-0578-3094
  • Camacho, Valle|||0000-0003-0748-0847
  • Lopez Mora, Diego Alfonso|||0000-0002-3533-7362
  • Fernández León, Alejandro|||0000-0002-1010-9451
  • Le Bastard, Nathalie
  • Huyck, Else
  • Nadal, Alicia
  • Olmedo, Verónica
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Montal, Victor|||0000-0002-5714-9282
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
To determine the cutoffs that optimized the agreement between 18 F-Florbetapir positron emission tomography (PET) and A β 1-42, A β 1-40, tTau, pTau and their ratios measured in cerebrospinal fluid (CSF) on the LUMIPULSE G600II instrument, we quantified the levels of these four biomarkers in 94 CSF samples from participants of the Sant Pau Initiative on Neurodegeneration (SPIN cohort) using the Lumipulse G System with available 18 F-Florbetapir imaging. Participants had mild cognitive impairment (n = 35), AD dementia (n = 12), other dementias or neurodegenerative diseases (n = 41), or were cognitively normal controls (n = 6). Levels of A β 1-42 were standardized to certified reference material. Amyloid scans were assessed visually and through automated quantification. We determined the cutoffs of CSF biomarkers that optimized their agreement with 18 F-Florbetapir PET and evaluated concordance between markers of the amyloid category. A β 1-42, tTau and pTau (but not A β 1-40) and the ratios with A β 1-42 had good diagnostic agreement with 18 F-Florbetapir PET. As a marker of amyloid pathology, the A β 1-42/A β 1-40 ratio had higher agreement and better correlation with amyloid PET than A β 1-42 alone. CSF biomarkers measured with the Lumipulse G System show good agreement with amyloid imaging in a clinical setting with heterogeneous presentations of neurological disorders. Combination of A β 1-42 with A β 1-40 increases the agreement between markers of amyloid pathology.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

The Aβ1-42/Aβ1-40 ratio in CSF is more strongly associated to tau markers and clinical progression than Aβ1-42 alone

  • Estellés, Teresa
  • Zhu, Nuole|||0000-0002-0015-9455
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Valldeneu, Silvia|||0000-0003-3497-886X
  • Subirana, Andrea
  • Tondo Colomer, Mireia|||0000-0002-0301-9984
  • Blanco Vaca, Francisco|||0000-0001-7380-5385
  • Lehmann, Sylvain|||0000-0001-6117-562X
  • Belbin, Olivia|||0000-0002-6109-6371
  • Blesa, Rafael|||0000-0003-4026-2884
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Cerebrospinal fluid (CSF) Aβ1-42 levels and the Aβ1-42/Aβ1-40 ratio are markers of amyloid pathology, but previous studies suggest that their levels might be influenced by additional pathophysiological processes. To compare Aβ1-42 and the Aβ1-42/Aβ1-40 ratio in CSF in different neurodegenerative disorders and study their association with other biomarkers (tTau, pTau181, and NfL) and with cognitive and functional progression. We included all participants from the Sant Pau Initiative on Neurodegeneration (SPIN) with CSF Aβ1-42 and Aβ1-42/Aβ1-40. Participants had diagnoses of Alzheimer's disease (AD), dementia with Lewy bodies, frontotemporal lobar degeneration-related syndromes, non-neurodegenerative conditions, or were cognitively normal. We classified participants as "positive" or "negative" according to each marker. We compared CSF levels of tTau, pTau181, and NfL between concordant and discordant groups through ANCOVA and assessed differences in cognitive (MMSE, FCSRT) and functional (GDS, CDR-SOB) progression using Cox regression and linear-mixed models. In the 1791 participants, the agreement between Aβ1-42 and Aβ1-42/Aβ1-40 was 78.3%. The Aβ1-42/Aβ1-40 ratio showed a stronger correlation with tTau and pTau181 than Aβ1-42 and an agreement with tTau and pTau181 of 73.1% and 77.1%, respectively. Participants with a low Aβ1-42/Aβ1-40 ratio showed higher tTau and pTau181 and worse cognitive and functional prognosis, regardless of whether they were positive or negative for Aβ1-42. The results were consistent across stages, diagnostic categories, and use of different cutoffs. Although Aβ1-42 and Aβ1-42/Aβ1-40 are considered markers of the same pathophysiological pathway, our findings provide evidence favoring the use of the Aβ1-42/Aβ1-40 ratio in clinical laboratories in the context of AD. The online version contains supplementary material available at 10.1186/s13195-022-00967-z.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Estellés, Teresa
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Muñoz, Lourdes
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lehmann, Stépánka
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. Among them, CSF neurofilament light (NfL) protein has particular interest, as its levels reflect neuroaxonal degeneration, a common feature in various neurodegenerative diseases. In the present study, we analyzed NfL levels in the CSF of 535 participants of the SPIN (Sant Pau Initiative on Neurodegeneration) cohort including cognitively normal participants, patients with Alzheimer disease (AD), Down syndrome (DS), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). We evaluated the differences in CSF NfL accross groups and its association with other CSF biomarkers and with cognitive scales. All neurogenerative diseases showed increased levels of CSF NfL, with the highest levels in patients with ALS, FTD, CBS and PSP. Furthermore, we found an association of CSF NfL levels with cognitive impairment in patients within the AD and FTD spectrum and with AD pathology in DLB and DS patients. These results have implications for the use of NfL as a marker in neurodegenerative diseases.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Hypothalamic pregnenolone mediates recognition memory in the context of metabolic disorders

  • Ramírez, Sara
  • Haddad-Tóvolli, Roberta
  • Radosevic, Marija
  • Toledo, Miriam
  • Pané, Adriana|||0000-0002-7810-1827
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Ribas Ripoll, Vicent|||0000-0002-7266-6106
  • Milà-Guasch, Maria
  • Pozo, Macarena
  • Obri, Arnaud
  • Eyre Sánchez, Elena
  • Gómez-Valadés, Alicia G.
  • Chivite, Iñigo
  • Van Eeckhout, Tomas
  • Zalachoras, Ioannis
  • Altirriba, Jordi
  • Bauder, Corinna
  • Imbernón, Mónica
  • Garrabou, Glòria|||0000-0001-8973-9933
  • Garcia-Ruiz, Carmen
  • Nogueiras, Rubén|||0000-0002-9976-9930
  • Soto, David
  • Gasull, Xavier|||0000-0002-6154-8323
  • Sandi, Carmen|||0000-0001-7713-8321
  • Brüning, Jens C.
  • Fortea, Juan|||0000-0002-1340-638X
  • Jiménez Pineda, Amanda|||0000-0003-4967-1174
  • Fernández-Checa, José C.
  • Claret, Marc
Obesity and type 2 diabetes are associated with cognitive dysfunction. Because the hypothalamus is implicated in energy balance control and memory disorders, we hypothesized that specific neurons in this brain region are at the interface of metabolism and cognition. Acute obesogenic diet administration in mice impaired recognition memory due to defective production of the neurosteroid precursor pregnenolone in the hypothalamus. Genetic interference with pregnenolone synthesis by Star deletion in hypothalamic POMC, but not AgRP neurons, deteriorated recognition memory independently of metabolic disturbances. Our data suggest that pregnenolone's effects on cognitive function were mediated via an autocrine mechanism on POMC neurons, influencing hippocampal long-term potentiation. The relevance of central pregnenolone on cognition was also confirmed in metabolically unhealthy patients with obesity. Our data reveal an unsuspected role for POMC neuron-derived neurosteroids in cognition. These results provide the basis for a framework to investigate new facets of POMC neuron biology with implications for cognitive disorders. Ramírez et al. show that reduced hypothalamic pregnenolone levels, in the context of metabolic diseases, are associated with cognitive deterioration. POMC neuron-derived pregnenolone is a key mediator of cognition, but not metabolism, acting via hippocampal mechanisms. These results identify an unsuspected role for POMC neuron-derived pregnenolone in memory performance.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Plasma glial fibrillary acidic protein and neurofilament light chain for the diagnostic and prognostic evaluation of frontotemporal dementia

  • Zhu, Nuole|||0000-0002-0015-9455
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Montal, Victor|||0000-0002-5714-9282
  • Estellés, Teresa
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Arranz Martínez, Javier|||0000-0003-0891-1215
  • Muñoz, Laia|||0000-0003-0578-3094
  • Belbin, Olivia|||0000-0002-6109-6371
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
  • Alcolea, Daniel|||0000-0002-3819-3245
Background: Astrocytes play an essential role in neuroinflammation and are involved in the pathogenesis of neurodenegerative diseases. Studies of glial fibrillary acidic protein (GFAP), an astrocytic damage marker, may help advance our understanding of different neurodegenerative diseases. In this study, we investigated the diagnostic performance of plasma GFAP (pGFAP), plasma neurofilament light chain (pNfL) and their combination for frontotemporal dementia (FTD) and Alzheimer's disease (AD) and their clinical utility in predicting disease progression. Methods: pGFAP and pNfL concentrations were measured in 72 FTD, 56 AD and 83 cognitively normal (CN) participants using the Single Molecule Array technology. Of the 211 participants, 199 underwent cerebrospinal (CSF) analysis and 122 had magnetic resonance imaging. We compared cross-sectional biomarker levels between groups, studied their diagnostic performance and assessed correlation between CSF biomarkers, cognitive performance and cortical thickness. The prognostic performance was investigated, analyzing cognitive decline through group comparisons by tertile. Results: Unlike pNfL, which was increased similarly in both clinical groups, pGFAP was increased in FTD but lower than in AD (all P < 0.01). Combination of both plasma markers improved the diagnostic performance to discriminate FTD from AD (area under the curve [AUC]: combination 0.78; pGFAP 0.7; pNfL 0.61, all P < 0.05). In FTD, pGFAP correlated with cognition, CSF and plasma NfL, and cortical thickness (all P < 0.05). The higher tertile of pGFAP was associated with greater change in MMSE score and poor cognitive outcome during follow-up both in FTD (1.40 points annually, hazard ratio [HR] 3.82, P < 0.005) and in AD (1.20 points annually, HR 2.26, P < 0.005). Conclusions: pGFAP and pNfL levels differ in FTD and AD, and their combination is useful for distinguishing between the two diseases. pGFAP could also be used to track disease severity and predict greater cognitive decline during follow-up in patients with FTD.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Sex-specific metabolic pathways were associated with alzheimer's disease (Ad) endophenotypes in the european medical information framework for ad multimodal biomarker discovery cohort

  • Xu, Jin
  • Green, Becki|||0000-0002-0513-5188
  • Kim, Min|||0000-0002-8769-4804
  • Lord, Jodie|||0000-0003-2955-7809
  • Ebshiana, Amera
  • Westwood, Sarah|||0000-0003-0506-7813
  • Baird, Alison
  • Nevado-Holgado, Alejo|||0000-0001-9276-2720
  • Shi, Liu|||0000-0003-1752-0419
  • Hye, Abdul|||0000-0003-2237-4823
  • Snowden, Stuart|||0000-0002-9419-5819
  • Bos, Isabelle|||0000-0001-9648-6428
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Vandenberghe, Rik|||0000-0001-6237-2502
  • Teunissen, Charlotte E.|||0000-0002-4061-0837
  • ten Kate, Mara|||0000-0002-8290-8543
  • Scheltens, Philip|||0000-0002-1046-6408
  • Gabel, Silvy
  • Meersmans, Karen
  • Blin, Olivier
  • Richardson, Jill|||0000-0001-6564-3187
  • De Roeck, Ellen
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • Sleegers, Kristel|||0000-0002-0283-2332
  • Bordet, Régis|||0000-0003-3916-6422
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Kettunen, Petronella|||0000-0002-2510-3423
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Verhey, Frans R. J.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Peyratout, Gwendoline
  • Tainta, Mikel|||0000-0003-0624-1211
  • Johannsen, Peter
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Froelich, Lutz|||0000-0003-1494-0813
  • Dobricic, Valerija|||0000-0001-8559-1097
  • Frisoni, Giovanni B.|||0000-0002-6419-1753
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Wallin, Anders|||0000-0001-9506-0513
  • Popp, Julius|||0000-0002-0068-0312
  • Martinez-Lage, Pablo|||0000-0001-5404-9967
  • Bertram, Lars|||0000-0002-0108-124X
  • Blennow, Kaj|||0000-0002-1890-4193
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Streffer, Johannes Rolf|||0000-0002-9387-5951
  • Visser, Pieter Jelle|||0000-0001-8008-9727
  • Lovestone, Simon|||0000-0003-0473-4565
  • Proitsi, Petroula|||0000-0002-2553-6974
  • Legido-Quigley, Cristina|||0000-0002-4018-214X
Background: physiological differences between males and females could contribute to the development of Alzheimer's Disease (AD). Here, we examined metabolic pathways that may lead to precision medicine initiatives. Methods: We explored whether sex modifies the association of 540 plasma metabolites with AD endophenotypes including diagnosis, cerebrospinal fluid (CSF) biomarkers, brain imaging, and cognition using regression analyses for 695 participants (377 females), followed by sex-specific pathway overrepresentation analyses, APOE ε4 stratification and assessment of metabolites' discriminatory performance in AD. Results: In females with AD, vanillylmandelate (tyrosine pathway) was increased and tryptophan betaine (tryptophan pathway) was decreased. The inclusion of these two metabolites (area under curve (AUC) = 0.83, standard error (SE) = 0.029) to a baseline model (covariates + CSF biomarkers, AUC = 0.92, SE = 0.019) resulted in a significantly higher AUC of 0.96 (SE = 0.012). Kynurenate was decreased in males with AD (AUC = 0.679, SE = 0.046). Conclusions: metabolic sex-specific differences were reported, covering neurotransmission and inflammation pathways with AD endophenotypes. Two metabolites, in pathways related to dopamine and serotonin, were associated to females, paving the way to personalised treatment.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Characteristics of subjective cognitive decline associated with amyloid positivity

  • Janssen, Olin|||0000-0002-8341-0958
  • Jansen, Willemijn J.
  • Vos, Stephanie J.B.|||0000-0002-2045-9818
  • Boada, Mercè|||0000-0003-2617-3009
  • Parnetti, Lucilla|||0000-0001-5722-3967
  • Gabryelewicz, Tomasz
  • Fladby, Tormod|||0000-0002-9984-9797
  • Molinuevo, José Luis|||0000-0003-0485-6001
  • Villeneuve, Sylvia
  • Hort, Jakub|||0000-0002-1080-3726
  • Epelbaum, Stéphane
  • Lleó, Alberto|||0000-0002-2568-5478
  • Engelborghs, Sebastiaan|||0000-0003-0304-9785
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Landau, Susan
  • Popp, Julius|||0000-0002-0068-0312
  • Wallin, Anders|||0000-0001-9506-0513
  • Scheltens, Philip|||0000-0002-1046-6408
  • Rikkert, Marcel Olde|||0000-0003-1397-1677
  • Snyder, Peter J.|||0000-0003-0555-4654
  • Rowe, Chris
  • Chételat, G.|||0000-0002-4889-7932
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Marquié, Marta|||0000-0002-0660-0950
  • Chipi, Elena
  • Wolfsgruber, Steffen
  • Heneka, Michael|||0000-0003-4996-1630
  • Boecker, Henning|||0000-0003-2346-0598
  • Peters, Oliver|||0000-0003-0568-2998
  • Jarholm, Jonas
  • Rami Gonzalez, Lorena|||0000-0002-7411-1921
  • Tort-Merino, Adrià|||0000-0002-5646-0482
  • Pichet Binette, Alexa|||0000-0001-5218-3337
  • Poirier, Judes
  • Rosa-Neto, Pedro|||0000-0001-9116-1376
  • Cerman, Jiri
  • Dubois, Bruno
  • Teichmann, Marc
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Fortea, Juan|||0000-0002-1340-638X
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Ebenau, Jarith
  • Pocnet, Cornelia
  • Eckerström, Marie
  • Thompson, Louisa
  • Villemagne, Victor
  • Buckley, Rachel|||0000-0002-5356-5537
  • Burnham, Samantha
  • Delarue, Marion
  • Freund-Levi, Yvonne|||0000-0001-6863-6679
  • Wallin, Åsa K.
  • Ramakers, Inez
  • Tsolaki, Magda|||0000-0002-2072-8010
  • Soininen, Hilkka|||0000-0002-2785-9937
  • Hampel, Harald
  • Spiru, Luiza
  • Tijms, Betty M.|||0000-0002-2612-1797
  • Ossenkoppele, Rik
  • Verhey, Frans
  • Jessen, Frank
  • Visser, Pieter Jelle|||0000-0001-8008-9727
Introduction: The evidence for characteristics of persons with subjective cognitive decline (SCD) associated with amyloid positivity is limited. Methods: In 1640 persons with SCD from 20 Amyloid Biomarker Study cohort, we investigated the associations of SCD-specific characteristics (informant confirmation, domain-specific complaints, concerns, feelings of worse performance) demographics, setting, apolipoprotein E gene (APOE) ε4 carriership, and neuropsychiatric symptoms with amyloid positivity. Results: Between cohorts, amyloid positivity in 70-year-olds varied from 10% to 76%. Only older age, clinical setting, and APOE ε4 carriership showed univariate associations with increased amyloid positivity. After adjusting for these, lower education was also associated with increased amyloid positivity. Only within a research setting, informant-confirmed complaints, memory complaints, attention/concentration complaints, and no depressive symptoms were associated with increased amyloid positivity. Feelings of worse performance were associated with less amyloid positivity at younger ages and more at older ages. Discussion: Next to age, setting, and APOE ε4 carriership, SCD-specific characteristics may facilitate the identification of amyloid-positive individuals.
Dipòsit Digital de Documents de la UAB
Publication Artículo científico (JournalArticle)

Agreement of cerebrospinal fluid biomarkers and amyloid-PET in a multicenter study

  • Guillén, Núria|||0000-0002-1341-9834
  • Contador, José
  • Buongiorno, Mariateresa
  • Alvarez, Ignacio|||0000-0002-8537-3935
  • Culell, Natalia
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Lleó, Alberto|||0000-0002-2568-5478
  • Fortea, Juan|||0000-0002-1340-638X
  • Piñol-Ripoll, Gerard
  • Carnes-Vendrell, Anna
  • Ispierto, María Lourdes|||0000-0002-1837-9675
  • Vilas Rolán, Dolores|||0000-0003-3084-053X
  • Puig-Pijoan, Albert|||0000-0002-9848-3711
  • Fernández-Lebrero, Aida|||0000-0002-2097-4430
  • Balasa, Mircea|||0000-0002-1795-4228
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
Core Alzheimer's disease (AD) cerebrospinal fluid (CSF) biomarkers have shown incomplete agreement with amyloid-positron emission tomography (PET). Our goal was to analyze the agreement between AD CSF biomarkers and amyloid-PET in a multicenter study. Retrospective multicenter study (5 centers). Participants who underwent both CSF biomarkers and amyloid-PET scan within 18 months were included. Clinical diagnoses were made according to latest diagnostic criteria by the attending clinicians. CSF Amyloid Beta (Aβ, A), phosphorliated tau 181 (pTau181, T) and total tau (tTau, N) biomarkers were considered normal (-) or abnormal (+) according to cutoffs of each center. Amyloid-PET was visually classified as positive/negative. Agreement between CSF biomarkers and amyloid-PET was analyzed by overall percent agreement (OPA). 236 participants were included (mean age 67.9 years (SD 9.1), MMSE score 24.5 (SD 4.1)). Diagnoses were mild cognitive impairment or dementia due to AD (49%), Lewy body dementia (22%), frontotemporal dementia (10%) and others (19%). Mean time between tests was 5.1 months (SD 4.1). OPA between single CSF biomarkers and amyloid-PET was 74% for , 75% for pTau181, 73% for tTau. The use of biomarker ratios improved OPA: 87% for Aβ/Aβ (n = 155), 88% for pTau181/Aβ (n = 94) and 82% for tTau/Aβ (n = 160). A + T + N + cases showed the highest agreement between CSF biomarkers and amyloid-PET (96%), followed by A-T-N- cases (89%). Aβ/Aβ was a better marker of cerebral amyloid deposition, as identified by amyloid tracers, than Aβ alone. Combined biomarkers in CSF predicted amyloid-PET result better than single biomarkers.